Fundraising FoxVisionary Ventures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Pelagepelagepharma.comin𝕏Oct 2025
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.
BiotechHealthtechLongevityLos Angeles, US
Heather Christofk(Executive Officer)William Lowry(PhD)inChristina Weng(Chief Medical Officer)inNathan Wheeler(Chief Operating Officer)in
BoardCathy Friedman(Director)inDaniel Gil(CEO)
Co-investorsGV (Google Ventures)ARCH Venture PartnersHAWKTAILYK Bioventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.